Targeted adenovirus-mediated transduction of human T cells in vitro and in vivo
Related Experiment Video
Updated: Aug 4, 2025
Adenoviral Transduction of Naive CD4 T Cells to Study Treg Differentiation
Published on: August 13, 2013
Patrick C Freitag1, Meike Kaulfuss2, Lea Flühler1
1Department of Biochemistry, University of Zurich, Winterthurerstrasse 190, 8057 Zurich, Switzerland.
Abstract:
Clinical success in T cell therapy has stimulated widespread efforts to increase safety and potency and to extend this technology to solid tumors. Yet progress in cell therapy remains restricted by the limited payload capacity, specificity of target cell transduction, and transgenic gene expression efficiency of applied viral vectors. This renders complex reprogramming or direct in vivo applications difficult. Here, we developed a synergistic combination of trimeric adapter constructs enabling T cell-directed transduction by the human adenoviral vector serotype C5 in vitro and in vivo. Rationally chosen binding partners showed receptor-specific transduction of otherwise non-susceptible human T cells by exploiting activation stimuli. This platform remains compatible with high-capacity vectors for up to 37 kb DNA delivery, increasing payload capacity and safety because of the removal of all viral genes. Together, these findings provide a tool for targeted delivery of large payloads in T cells as a potential avenue to overcome current limitations of T cell therapy.
Insights
Researchers developed a novel method for T-cell therapy, enhancing gene delivery using adenoviral vectors. This breakthrough improves T-cell transduction efficiency and safety for treating solid tumors.
Area of Science:
- Immunology
- Gene Therapy
- Oncology
Background:
- T-cell therapy shows promise for solid tumors but faces limitations.
- Current viral vectors have restricted payload capacity and target specificity.
- Complex reprogramming and in vivo applications are hindered by these limitations.
Purpose of the Study:
- To develop a novel platform for enhanced T-cell transduction.
- To overcome limitations in viral vector payload capacity and specificity.
- To enable efficient gene delivery for T-cell therapy applications.
Main Methods:
- Developed trimeric adapter constructs for T-cell-directed transduction.
- Utilized human adenoviral vector serotype C5 for in vitro and in vivo delivery.
- Employed receptor-specific binding partners and activation stimuli for targeted transduction.
Main Results:
- Achieved T-cell-directed transduction using adenoviral vectors.
- Demonstrated receptor-specific transduction of human T-cells.
- Platform supports high-capacity vectors (up to 37 kb DNA) with enhanced safety by removing viral genes.
Conclusions:
- The developed platform enables targeted delivery of large payloads in T-cells.
- This approach offers a potential solution to current T-cell therapy limitations.
- Provides a tool for advancing T-cell therapy, particularly for solid tumors.
